The KRYSTAL-1 also investigated adagrasib monotherapy for previously treated advanced KRAS G12C-mutated CRC and showed an ORR of 19% with an mPFS of 5.6 months (20). This evidence concerns the gene KRAS and colorectal carcinoma.